Johnson & Johnson And Tianjin Cancer Hospital To Conduct Joint Drug Research
This article was originally published in PharmAsia News
Johnson & Johnson and Cancer Hospital of Tianjin Medical University have signed an MOU to jointly develop oncology drugs. Both parties are also discussing the possibility of setting up an oncology R&D collaboration center in Tianjin's Binhai Hi-tech Industrial Park. Cancer Hospital is one of China's largest tumor prevention and treatment bases, housing an advanced tissue bank for tumor specimens. With its strong clinical techniques and resources, the hospital will make an ideal partner for Johnson & Johnson, which seeks to build up a cancer drug R&D base in Asia Pacific. Areas of cooperation will cover animal model studies, local and global clinical trials, technology and knowledge transfer, as well as training for clinicians and researchers. (Click here for more - Chinese language)
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.